Vista Partners Initiates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 01/13/15 -- announced today that it has initiated coverage on (OTCQB: ONCS) ("the Company") based in San Diego, CA, with a twelve month price target of $1.20. Ross Silver, Principal Analyst at Vista Partners, stated, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents."
To download a FREE copy of the research report, please visit and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Please follow us on & at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click .
Contact:
Vista Partners
877.215.4813
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.01.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 364005
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 254 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Initiates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20"
steht unter der journalistisch-redaktionellen Verantwortung von
Vista Partners (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
